Virtus LifeSci Biotech Clinical Trials ETF
16 hedge funds and large institutions have $5.28M invested in Virtus LifeSci Biotech Clinical Trials ETF in 2016 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 2 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more ownership
Funds ownership: →
more funds holding
Funds holding: →
2% less capital invested
Capital invested by funds: $5.39M → $5.28M (-$110K)
Holders
16
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
1 | +$433K | |
2 | +$426K | |
3 | +$299K | |
4 |
CCP
Cardan Capital Partners
Denver,
Colorado
|
+$127K |
5 |
SG Americas Securities
New York
|
+$66.4K |
Top Sellers
1 | -$569K | |
2 | -$46.1K | |
3 | -$26.5K | |
4 |
NFG
Next Financial Group
Houston,
Texas
|
-$15K |
5 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
-$10.1K |